Histopathological Predictors of Recurrence in Stage III Colon Cancer: Reappraisal of Tumor Deposits and Tumor Budding Using AJCC8 Criteria

被引:29
作者
Landau, Michael A. [1 ]
Zhu, Benjamin [1 ]
Akwuole, Frances N. [1 ]
Pai, Reetesh K. [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
关键词
colon cancer; tumor deposit; tumor budding; survival; stage IIl; KRAS; BRAF; MSI; mismatch repair; COLORECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE; VENOUS INVASION; LYMPH-NODES; TNM; IMPACT; ADENOCARCINOMA; CARCINOMA; KRAS;
D O I
10.1177/1066896918787275
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Patients with stage III colonic adenocarcinoma have a spectrum of risk for recurrent disease, and histopathological variables that predict recurrence can help stratify patients into prognostic groups. To identify histopathological predictors of recurrence, we investigated the effect of implementation of the eighth edition of the American Joint Committee on Cancer (AJCC8) staging system definition of tumor deposits and International Tumor Budding Consensus Conference (ITBCC) criteria for tumor budding compared with other known prognostic variables in 256 resected colonic adenocarcinomas, including 150 stage III and 106 stage II tumors. In stage III colon cancer, tumor deposits and high tumor budding were the only independent histological variables that predicted disease recurrence. In a multivariable analysis in stage III colon cancer, tumor deposits and high tumor budding were associated with a 2.2- and 1.5-fold increased risk of developing disease recurrence, respectively (95% CI = 1.1-4,2, P = .02, and 95% CI = 1.1-2.1, P = .01, respectively). The negative prognostic effect of tumor deposits was most pronounced in patients with stage IIIB disease in which tumor deposits were associated with a 3.2-fold increased risk of disease recurrence (95% CI = 1.4-7.1; P = .005). Within the N1 cohort, patients with tumor deposits without concurrent positive lymph nodes (N1c) had a significantly decreased disease-free survival compared with patients with N0 tumors (P < .001) and patients with N1a/b tumors (P = .02). As independent risk factors for recurrence, tumor deposits and high tumor budding are important histopathological variables and should be included as a part of a routine comprehensive pathological risk assessment in stage III colon cancer.
引用
收藏
页码:147 / 158
页数:12
相关论文
共 33 条
  • [11] Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer
    Horcic, Milo
    Koelzer, Viktor H.
    Karamitopoulou, Eva
    Terracciano, Luigi
    Puppa, Giacomo
    Zlobec, Inti
    Lugli, Alessandro
    [J]. HUMAN PATHOLOGY, 2013, 44 (05) : 697 - 705
  • [12] Jin M, 2015, AM J SURG PATHOL, V39, P109, DOI 10.1097/PAS.0000000000000320
  • [13] Kakar S., Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum
  • [14] Venous Invasion in Colorectal Cancer Impact of an Elastin Stain on Detection and Interobserver Agreement Among Gastrointestinal and Nongastrointestinal Pathologists
    Kirsch, Richard
    Messenger, David E.
    Riddell, Robert H.
    Pollett, Aaron
    Cook, Megan
    Al-Haddad, Sahar
    Streutker, Catherine J.
    Divaris, Dimitrios X.
    Pandit, Rajani
    Newell, Ken J.
    Liu, Jimin
    Price, Russell G.
    Smith, Sharyn
    Parfitt, Jeremy R.
    Driman, David K.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (02) : 200 - 210
  • [15] Tumor budding in colorectal cancer-ready for diagnostic practice?*'**
    Koelzer, Viktor H.
    Zlobec, Inti
    Lugli, Alessandro
    [J]. HUMAN PATHOLOGY, 2016, 47 (01) : 4 - 19
  • [16] Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer
    Lai, Y. -H.
    Wu, L. -C.
    Li, P. -S.
    Wu, W. -H.
    Yang, S. -B.
    Xia, P.
    He, X. -X.
    Xiao, L. -B.
    [J]. COLORECTAL DISEASE, 2014, 16 (04) : 259 - 264
  • [17] Site-specific Differences in Colonic Adenocarcinoma KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma
    Landau, Michael A.
    Zhu, Benjamin
    Akwuole, Frances N.
    Pai, Reetesh K.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (03) : 351 - 358
  • [18] Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016
    Lugli, Alessandro
    Kirsch, Richard
    Ajioka, Yoichi
    Bosman, Fred
    Cathomas, Gieri
    Dawson, Heather
    El Zimaity, Hala
    Flejou, Jean-Francois
    Hansen, Tine Plato
    Hartmann, Arndt
    Kakar, Sanjay
    Langner, Cord
    Nagtegaal, Iris
    Puppa, Giacomo
    Riddell, Robert
    Ristimaki, Ari
    Sheahan, Kieran
    Smyrk, Thomas
    Sugihara, Kenichi
    Terris, Benoit
    Ueno, Hideki
    Vieth, Michael
    Zlobec, Inti
    Quirke, Phil
    [J]. MODERN PATHOLOGY, 2017, 30 (09) : 1299 - 1311
  • [19] Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome
    Messenger, David E.
    Driman, David K.
    Kirsch, Richard
    [J]. HUMAN PATHOLOGY, 2012, 43 (07) : 965 - 973
  • [20] Colorectal tumour deposits in the mesorectum and pericolon; a critical review
    Nagtegaal, I. D.
    Quirke, P.
    [J]. HISTOPATHOLOGY, 2007, 51 (02) : 141 - 149